OptimizeRx Co. (NASDAQ:OPRX) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Shares of OptimizeRx Co. (NASDAQ:OPRX) have been assigned a consensus rating of “Moderate Buy” from the nine ratings firms that are covering the firm, MarketBeat Ratings reports. Three research analysts have rated the stock with a hold recommendation and six have assigned a buy recommendation to the company. The average 1 year target price among brokerages that have issued ratings on the stock in the last year is $9.06.

A number of equities research analysts have commented on OPRX shares. William Blair reissued an “outperform” rating on shares of OptimizeRx in a report on Thursday, November 14th. B. Riley decreased their price target on OptimizeRx from $17.00 to $13.00 and set a “buy” rating on the stock in a report on Tuesday, December 24th. Barclays decreased their price target on OptimizeRx from $11.00 to $5.00 and set an “equal weight” rating on the stock in a report on Thursday, November 14th. Stifel Nicolaus decreased their price target on OptimizeRx from $13.00 to $8.00 and set a “buy” rating on the stock in a report on Thursday, November 14th. Finally, Lake Street Capital reaffirmed a “buy” rating and issued a $11.00 target price on shares of OptimizeRx in a report on Tuesday, December 24th.

OptimizeRx Price Performance

NASDAQ:OPRX opened at $5.11 on Friday. The company has a quick ratio of 3.23, a current ratio of 3.23 and a debt-to-equity ratio of 0.29. The business’s 50-day simple moving average is $5.44 and its two-hundred day simple moving average is $6.17. The stock has a market cap of $94.13 million, a PE ratio of -3.84 and a beta of 1.38. OptimizeRx has a 52 week low of $3.78 and a 52 week high of $16.65.

Insider Transactions at OptimizeRx

In other OptimizeRx news, CEO William J. Febbo bought 20,000 shares of the business’s stock in a transaction dated Thursday, December 12th. The shares were purchased at an average price of $5.01 per share, with a total value of $100,200.00. Following the completion of the purchase, the chief executive officer now owns 601,253 shares in the company, valued at $3,012,277.53. This represents a 3.44 % increase in their position. The purchase was disclosed in a legal filing with the SEC, which is available at the SEC website. Insiders own 6.10% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the company. BNP Paribas Financial Markets grew its stake in OptimizeRx by 189.2% in the third quarter. BNP Paribas Financial Markets now owns 3,690 shares of the company’s stock worth $28,000 after purchasing an additional 2,414 shares in the last quarter. SBI Securities Co. Ltd. purchased a new stake in OptimizeRx during the fourth quarter worth $25,000. Quest Partners LLC lifted its holdings in OptimizeRx by 15,965.6% during the third quarter. Quest Partners LLC now owns 9,800 shares of the company’s stock worth $76,000 after buying an additional 9,739 shares during the period. SG Americas Securities LLC purchased a new stake in OptimizeRx during the fourth quarter worth $51,000. Finally, Wells Fargo & Company MN lifted its holdings in OptimizeRx by 33.3% during the fourth quarter. Wells Fargo & Company MN now owns 11,208 shares of the company’s stock worth $54,000 after buying an additional 2,797 shares during the period. Institutional investors own 76.47% of the company’s stock.

About OptimizeRx

OptimizeRx Corporation, a digital health technology company, enables care-focused engagement between life sciences organizations, healthcare providers, and patients at critical junctures throughout the patient care journey. It offers various tech-enabled marketing solutions through its Artificial Intelligence-generated Dynamic Audience and Activation Platform, which enables customers to execute traditional marketing campaigns on its proprietary digital point-of-care network, as well as dynamic marketing campaigns that optimize audiences in real time to increase the value of treatment information for healthcare professionals and patients in response to clinical care events.